ES2171749T3 - Composiciones farmaceuticas que contienen inhibidores de la agregacion de plaquetas. - Google Patents

Composiciones farmaceuticas que contienen inhibidores de la agregacion de plaquetas.

Info

Publication number
ES2171749T3
ES2171749T3 ES96940256T ES96940256T ES2171749T3 ES 2171749 T3 ES2171749 T3 ES 2171749T3 ES 96940256 T ES96940256 T ES 96940256T ES 96940256 T ES96940256 T ES 96940256T ES 2171749 T3 ES2171749 T3 ES 2171749T3
Authority
ES
Spain
Prior art keywords
aggregation
plates
pharmaceutical compositions
compositions containing
containing inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96940256T
Other languages
English (en)
Inventor
Karl M Gelotte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603721.3A external-priority patent/GB9603721D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2171749T3 publication Critical patent/ES2171749T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA INVENCION ES UN COMPUESTO FARMACEUTICO PARA ADMINISTRACION INTRAVENOSA QUE CONSTA DE: A) UNA CANTIDAD FARMACEUTICAMENTE EFICAZ DE UN COMPUESTO DE FORMULA (I), POR EJEMPLO, EL ACIDO 2 S - (N - BUTILSULFONILAMINO) - 3 - [4 - ( - (PIPERIDIN 4 IL)BUTILOXI)FENIL]PROPIONICO; B) UNA CANTIDAD FARMACEUTICAMENTE ACEPTABLE DE UN TAMPON DE CITRATO EFICAZ PARA PROPORCIONAR UN PH APROXIMADO DE ENTRE 5 Y 7, Y C) UNA CANTIDAD FARMACEUTICAMENTE ACEPTABLE DE UN AGENTE AJUSTADOR DE LA TONICIDAD EFICAZ PARA QUE LA FORMULACION SEA ESENCIALMENTE ISOTONICA CON LA PRESION OSMOTICA DEL SISTEMA BIOLOGICO DEL PACIENTE.
ES96940256T 1995-10-27 1996-10-23 Composiciones farmaceuticas que contienen inhibidores de la agregacion de plaquetas. Expired - Lifetime ES2171749T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US590795P 1995-10-27 1995-10-27
GBGB9603721.3A GB9603721D0 (en) 1996-02-22 1996-02-22 Composition for inhibiting platelet aggregation

Publications (1)

Publication Number Publication Date
ES2171749T3 true ES2171749T3 (es) 2002-09-16

Family

ID=26308777

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96940256T Expired - Lifetime ES2171749T3 (es) 1995-10-27 1996-10-23 Composiciones farmaceuticas que contienen inhibidores de la agregacion de plaquetas.

Country Status (35)

Country Link
EP (1) EP0859634B1 (es)
JP (1) JP3452367B2 (es)
KR (1) KR100362799B1 (es)
CN (1) CN1158107C (es)
AT (1) ATE213648T1 (es)
AU (1) AU712755B2 (es)
BG (1) BG63623B1 (es)
BR (1) BR9610878A (es)
CA (1) CA2234364C (es)
CO (1) CO4770960A1 (es)
CY (1) CY2292B1 (es)
CZ (1) CZ290381B6 (es)
DE (1) DE69619540T2 (es)
DK (1) DK0859634T3 (es)
DZ (1) DZ2110A1 (es)
EA (1) EA000628B1 (es)
EE (1) EE03518B1 (es)
ES (1) ES2171749T3 (es)
HK (1) HK1017846A1 (es)
HU (1) HU228757B1 (es)
IL (1) IL123790A (es)
IS (1) IS1948B (es)
MX (1) MX9803275A (es)
MY (1) MY116837A (es)
NO (1) NO324415B1 (es)
NZ (1) NZ323134A (es)
PL (1) PL185744B1 (es)
PT (1) PT859634E (es)
SA (1) SA96170527B1 (es)
SI (1) SI0859634T1 (es)
SK (1) SK282353B6 (es)
TR (1) TR199800716T2 (es)
TW (1) TW385248B (es)
UA (1) UA45423C2 (es)
WO (1) WO1997015328A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ633900A0 (en) 2000-03-20 2000-04-15 Jurox Pty Ltd Anaesthetic composition
CN1322863C (zh) * 2004-10-29 2007-06-27 武汉远大制药集团股份有限公司 一种抑制血小板凝聚的注射液及其制备方法
CN100386079C (zh) * 2005-03-24 2008-05-07 武汉远大制药集团股份有限公司 一种抑制血小板凝聚的注射用粉针及其制备方法
CN100367961C (zh) * 2005-09-30 2008-02-13 天津南开允公医药科技有限公司 盐酸替罗非班冻干粉针注射剂及其制备方法
CN102125519B (zh) * 2011-02-28 2012-07-11 正大青春宝药业有限公司 稳定的盐酸替罗非班注射液及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931441A (en) * 1988-11-09 1990-06-05 Luitpold Pharmaceuticals, Inc. Stabilized aqueous leucovorin calcium compositions
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
EP0859634A1 (en) 1998-08-26
EA000628B1 (ru) 1999-12-29
KR100362799B1 (ko) 2003-07-16
IL123790A (en) 2001-11-25
CO4770960A1 (es) 1999-04-30
DE69619540T2 (de) 2002-08-22
EP0859634B1 (en) 2002-02-27
MY116837A (en) 2004-04-30
IS4699A (is) 1998-03-24
PL326419A1 (en) 1998-09-14
UA45423C2 (uk) 2002-04-15
AU7718996A (en) 1997-05-15
MX9803275A (es) 1998-09-30
NO981869L (no) 1998-04-24
CY2292B1 (en) 2003-07-04
CN1158107C (zh) 2004-07-21
TW385248B (en) 2000-03-21
EE9800134A (et) 1998-10-15
BG102405A (en) 1999-08-31
CZ127898A3 (cs) 1998-10-14
HUP9902521A2 (hu) 1999-12-28
ATE213648T1 (de) 2002-03-15
DE69619540D1 (de) 2002-04-04
HU228757B1 (en) 2013-05-28
JPH10512296A (ja) 1998-11-24
NO981869D0 (no) 1998-04-24
AU712755B2 (en) 1999-11-18
BG63623B1 (bg) 2002-07-31
DZ2110A1 (fr) 2002-07-22
CN1200676A (zh) 1998-12-02
CA2234364A1 (en) 1997-05-01
DK0859634T3 (da) 2002-03-25
HUP9902521A3 (en) 2000-01-28
KR19990067020A (ko) 1999-08-16
CZ290381B6 (cs) 2002-07-17
WO1997015328A1 (en) 1997-05-01
HK1017846A1 (en) 1999-12-03
BR9610878A (pt) 1999-07-13
IS1948B (is) 2004-10-13
SI0859634T1 (en) 2002-04-30
EA199800336A1 (ru) 1998-10-29
PL185744B1 (pl) 2003-07-31
CA2234364C (en) 2000-02-08
IL123790A0 (en) 1998-10-30
SK51298A3 (en) 1998-12-02
NO324415B1 (no) 2007-10-08
SA96170527B1 (ar) 2005-12-21
NZ323134A (en) 1999-11-29
EE03518B1 (et) 2001-10-15
PT859634E (pt) 2002-07-31
JP3452367B2 (ja) 2003-09-29
TR199800716T2 (xx) 1998-07-21
SK282353B6 (sk) 2002-01-07

Similar Documents

Publication Publication Date Title
GEP20002298B (en) Benzimidazole Derivatives, Method of Their Production, Pharmaceutical Composition Containing the Same and Method for Its Treatment
RU95102778A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования потерь костной ткани и снижения уровня холестерина в сыворотке, фармацевтический препарат, содержащий 2-фенил-3-ароилбензотиофен
GEP20033117B (en) Hydroxy Pipecolate Hydroxamic Acid Derivatives as MMP Inhibitors, Pharmaceutical Compositions Containing Them and Their Use for Treatment of Diseases caused by MMP
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
ES2159591T3 (es) Composicion de liberacion controlada.
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
SE9901573D0 (sv) New compounds
FI821253A0 (fi) Galenisk produkt
IL113137A0 (en) Pharmaceutical compositions containing carboxylic acid derivatives
SE8700714L (sv) Anvendning av substituerade 4-fenyl-4-oxo-2-butensyraderivat for framstellning av lekemedel for behandling av sjukdomar i matsmeltningskanalen och som antiulcerost lekemedel
ES2171749T3 (es) Composiciones farmaceuticas que contienen inhibidores de la agregacion de plaquetas.
LV10267A (lv) Savienojums arstniecibas lidzeklis panemiens savienojuma iegusanai
AR035006A1 (es) Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.
ATE13488T1 (de) Gallium-chlorid, ein neues antikrebsmittel.
EP1027051A4 (en) ANTITHROMBOTIC AGENTS
GB9126874D0 (en) Medicaments
ES2123808T3 (es) Derivado de acilfenilglicina y agente profilactico y curativo para enfermedades causadas por una actividad acrecentada de colagenasa, que contiene dicho compuesto como ingrediente activo.
NO950177D0 (no) Farmakologisk aktive erivater
ATE189214T1 (de) Prostaglandinderivate
MX9302832A (es) Nuevo medicamento para el tratamiento de la arritmia.
ES2179667T3 (es) Nuevas formulaciones inyectables que contienen ramoplanina.
AR004223A1 (es) Composiciones para inhibir la agregacion de plaquetas y el uso de las mismas en la manufactura de un medicamento.
AR026285A1 (es) Profarmacos de higromicina a
EP0980366A4 (en) ANTITHROMOSIS

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 859634

Country of ref document: ES